Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC

NCT06475196 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Resectable Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Sintilimab (PD-1 inhibitor)

Sponsor

Tang-Du Hospital